

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3320)

ANNUAL GENERAL MEETING HELD ON 19 MAY 2017 – POLL RESULTS

The Company is pleased to announce that all the resolutions set out in the notice of AGM were duly passed by the shareholders of the Company by way of poll at the AGM.

China Resources Pharmaceutical Group Limited (the “**Company**”) is pleased to announce the poll results in respect of the resolutions proposed at the annual general meeting (the “**AGM**”) of the Company held on 19 May 2017 as follows:

Ordinary Resolutions proposed at the AGM		Number of Votes (%)	
		For	Against
1.	To receive and consider the audited financial statements, the directors’ report and the independent auditor’s report of the Company for the year ended 31 December 2016.	5,381,428,210 (99.99%)	500 (0.01%)
The resolution was duly passed as an ordinary resolution.			
2.	To declare a final dividend of HK\$0.09 per share for the year ended 31 December 2016.	5,381,599,210 (99.99%)	500 (0.01%)
The resolution was duly passed as an ordinary resolution.			

Ordinary Resolutions proposed at the AGM		Number of Votes (%)	
		For	Against
3.	(1) To re-elect Mr. LI Guohui as Director.	5,380,385,210 (99.98%)	1,214,500 (0.02%)
The resolution was duly passed as an ordinary resolution.			
	(2) To re-elect Mr. CHEN Rong as Director.	5,380,385,210 (99.98%)	1,214,500 (0.02%)
The resolution was duly passed as an ordinary resolution.			
	(3) To re-elect Mr. YU Zhongliang as Director.	5,380,385,210 (99.98%)	1,214,500 (0.02%)
The resolution was duly passed as an ordinary resolution.			
	(4) To re-elect Ms. WANG Jing as Director.	5,380,386,210 (99.98%)	1,214,500 (0.02%)
The resolution was duly passed as an ordinary resolution.			
	(5) To authorise the board of directors to fix the remuneration of the directors of the Company.	5,377,070,210 (99.99%)	500 (0.01%)
The resolution was duly passed as an ordinary resolution.			
4.	To re-appoint Messrs. Deloitte Touche Tohmatsu as the auditor of the Company and to authorise the Board to fix their remuneration.	5,381,599,210 (99.99%)	500 (0.01%)
The resolution was duly passed as an ordinary resolution.			
5.	Ordinary Resolution in item No.5 of the notice of AGM (To give a general mandate to the Directors to buy back shares of the Company).	5,381,595,210 (99.99%)	5,500 (0.01%)
The resolution was duly passed as an ordinary resolution.			
6.	Ordinary Resolution in item No.6 of the notice of AGM (To give a general mandate to the Directors to issue new shares of the Company).	5,303,158,161 (98.54%)	78,442,549 (1.46%)
The resolution was duly passed as an ordinary resolution.			

Ordinary Resolutions proposed at the AGM		Number of Votes (%)	
		For	Against
7.	Ordinary Resolution in item No.7 of the notice of AGM (To extend the general mandate to be given to the Directors to issue new shares of the Company).	5,303,154,161 (98.54%)	78,446,549 (1.46%)
The resolution was duly passed as an ordinary resolution.			

As at the date of the AGM, the total number of issued and fully paid up shares of the Company was 6,284,506,461 shares. In relation to all resolutions proposed at the AGM, the total number of shares entitling the holders to attend and vote for or against the resolutions at the AGM was 6,284,506,461 shares. There were no shares entitling the holders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and there were no shares requiring the holders to abstain from voting at the AGM under the Listing Rules. No shareholders of the Company have stated their intention in the circular of the Company dated 13 April 2017 (the “**Circular**”) to vote against or to abstain from voting on any of the proposed resolutions at the AGM.

Tricor Investor Services Limited, the Share Registrar of the Company, acted as scrutineers for the vote-taking at the AGM.

Shareholders may refer to the Circular for details of the above resolutions proposed at the AGM. The Circular may be viewed and downloaded from the Company’s website at www.crpharm.com or the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk.

For and on behalf of
China Resources Pharmaceutical Group Limited
WANG Chuncheng
Executive Director

Hong Kong, 19 May 2017

As of the date of this announcement, the Board of Directors of the Company comprises Mr. FU Yuning as chairman and non-executive Director, Mr. WANG Chuncheng, Mr. SONG Qing and Mr. LI Guohui as executive Directors, Mr. CHEN Rong, Mr. YU Zhongliang, Mr. WANG Chenyang and Ms. WANG Jing as non-executive Directors, Mr. TSANG Hing Lun, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.